March 3, 2016 | Israeli medical device startup Medasense Biometrics, has closed an $8 million Series B financing round, led by Benslie International. Founded in 2008 by CEO Galit Zuckerman, Medasense Biometrics has developed a platform technology that can assess and monitor changes in a patient’s pain level by processing multiple physiological parameters affected by pain and by analgesic administration. Medasense will use the new funding to accelerate commercialization of its flagship product PMD-200™: An objective pain monitoring system for operating rooms and critical care, where patients under general anesthesia are unable to communicate their pain. The system consists of a non-invasive finger probe that records multiple pain-related physiological signals, and the PMD-200™ monitor, which uses a composite algorithm to determine an individual’s real-time, pain level index NoL™.
Facebook comments